The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
BUSINESS
Relumina Submitted for Endometriosis Use in Japan: ASKA
ASKA Pharmaceutical said on January 28 that it has filed an application in Japan seeking to expand the label of its gonadotropin-releasing hormone (GnRH) receptor antagonist Relumina Tablets (relugolix) for the treatment of endometriosis. Relumina was approved in January 2019…
To read the full story
Related Article
- ASKA Launches Japan PIII of Relugolix Combo for Endometriosis
June 26, 2025
- ASKA Begins Japan PIII for Relugolix Combo Drug
December 17, 2024
- ASKA Extends Relugolix Combo Deal with Takeda into Endometriosis
June 3, 2024
- ASKA Begins Japan PI/II for Relugolix Combo Drug
July 21, 2023
- ASKA Earns Japan Rights to Takeda’s Relugolix Combo Drug
September 28, 2021
- Relumina Non-Inferior to Leuprorelin in Japan PIII Study for Endometriosis: ASKA
March 16, 2021
- Relugolix Nets Positive PIII Data in Endometriosis, ASKA Set to Seek Add’l Use in H1 2021
November 26, 2020
- ASKA Takes Over Uterine Fibroids Drug Relumina from Takeda
February 18, 2020
- Takeda Licenses Relugolix to ASKA in Women’s Health Field
June 1, 2018
BUSINESS
- Tokyo Court Tosses Nihon Generic’s Suit over Bayer’s Xarelto Patent Communications
December 18, 2025
- Xarelto Generics Win Adult, Pediatric VTE Indication Expansions
December 18, 2025
- AI-Driven Target Discovery Gains Ground among Japanese Pharma: FRONTEO CEO
December 17, 2025
- Enhertu Combo Wins US FDA Nod in 1st-Line HER2 Breast Cancer
December 17, 2025
- Pfizer Releases Nurtec Migraine Drug in Japan
December 17, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…